Global Biocomposites Market Report to 2027 – Rising Demand for Durable and Environmentally Friendly Manufacturing Materials is Driving Growth – ResearchAndMarkets.com

By -
DUBLIN--(BUSINESS WIRE)--The "Global Biocomposites Market Size, Trends and Growth Opportunity, By Type, Process, Fiber Type, Product, End user, By Region and Forecast to 2027." report has been added to ResearchAndMarkets.com's offering. The Global Biocomposites Market was valued at US$24.3 billion in 2021 and it is expected to reach at US$80.2 billion in 2027 at a CAGR of 15.59% during forecast period 2022-2027. Companies Mentioned UPM (Finland) Trex Company Inc. (U.S.) Fiberon (U.S.) Flexform SpA (U.S.) UFP Industries Inc. (U.S.) Meshlin Composites ZRT (Hungary) Tecnaro GmbH (Germany) Anhui Guofeng Wood-Plastic Composite Co. Ltd. (China) B.COMPOSITES PVT.LTD. (India) Green Dot Corporation (U.S.) Natural fibres including hemp, wood and paper waste, jute, and flax are combined with a polymer matrix to create biocomposites. From construction to packing to autos, these composites have a wide range of uses. Environmentally friendly biocomposites have become well-liked building materials. Additionally, throughout the projected period, tight environmental regulations are anticipated to support the expansion of the biocomposite market. Market Drivers The aerospace and defence industries' need for biocomposite will result in exceptionally high demand for the bio-based product. The current increase in the usage of biocomposite in the aerospace industry for the production of aircraft equipment, which demands ultra-advanced composites that can maintain the product, is anticipated to be the primary driver of the market for biocomposites. Furthermore, the main factor anticipated to propel the growth rate of the biocomposites market is the rise in demand for durable and environmentally friendly manufacturing materials. Market Restraints The market's expansion may be constrained by the high availability of biocomposites' competitors on the market, such as carbon fibre and glass fibres. Compared to carbon fibre and glass fibre composites, biocomposites are less durable. The key factor that impeding the growth of the global biocomposites market. Impact of COVID-19 on Biocomposites Market The market for biocomposites was negatively impacted by the coronavirus outbreak. Because of this epidemic, the government has enacted strict international regulations, which have negatively impacted the development of the biocomposites market. Due to the falling demand for biocomposites internationally, the major end markets for these materials, including the automotive, building, aerospace, and other sectors, have likewise stopped producing them. Additionally, the majority of the market's raw material suppliers for biocomposites have stopped doing business, and the main suppliers have shifted their focus to pandemic relief. Market Segmentation By Type Structural Non-Structural By Process Compression Molding Injection Molding Resin Transfer Molding Others By Product Hybrid Green By Fiber Type Fiber Non-Wood Fiber By End User Building And Construction Transportation Consumer Goods Key Question Addressed by the Report
http://dlvr.it/Scbn3L

Comments

Post a Comment

Popular posts from this blog

Hempy 2014!

By -
Image
I started 2013 with a basement full of weed and an empty bank account. I don’t know of any Seattle growers that actually got rich from growing pot this year. I think a lot of us unemployed corporate types who were laid off saw the opportunity to work for ourselves until the state could figure out what to do with the future of medical and voter approved recreational pot. A year later, the future of  medical marijuana in Washington State is still tenuous.  I have personally witnessed healing in people who use cannabis as medicine and I think it’s a crime that providers have been thrown in jail for helping others. Cannabis IS medicine and we have a God-given right to have access to it. Dispensary “donations” were my main source of income in 2013. I make half of what I used to back in my VC-funded days, but I don’t care. Money is not it. Helping people, and loving what you do on a daily basis where it’s at, man. The meaning of life is to be of service to others. Working
Read more

Coming Out of the Pot Closet

By -
Image
I have to vacuum before my mother arrives from Arizona. I’m 40-something years old and I still want her housekeeping approval. While we’re close, and speak on the phone every week, we haven’t seen each other 1:1 for a while. I’m freaking out because I think she’ll have an aneurysm when I tell her how I’ve been paying my bills the past three years. Garden of Eve The time has arrived for me to come out of the Pot Closet to my mother. How did I get here? I was laid off from my event-planning job while dating a “normal-looking” guy, who owned his own landscaping business. “Larry” also happen to own a basement full of marijuana plants for extra spending money (on prostitutes, as it turns out, but that’s a different blog post). He taught me everything I know about being a Pharmer -- from cloning and transplanting, to providing my babies with the proper nutrients and watering techniques.  I learned a lot – about the miraculous cannabis plant, and about the lying, cheating asshol
Read more

PureTech Provides End of Year Report on Key Progress

By -
Image
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today reported on the key progress made across its Wholly Owned Programs1 and Founded Entities2 in 2022. Daphne Zohar, Founder and Chief Executive Officer of PureTech, commented: “2022 has been a particularly successful and productive year in both crystallizing value and shaping the future of PureTech. Our primary focus is to progress our Wholly Owned Pipeline to commercialization and deliver new classes of medicines for patients with serious, debilitating conditions. We are advancing toward this goal by deepening our commitment to programs with compelling clinical data that are moving into late-stage studies and that we believe have the potential for broad impact. “Over the next 12 months, we anticipate multiple important catalysts that will further guide how we prioritize o
Read more